Scienture Holdings, Inc.
SCNXHealthcareNASDAQPharmaceutical Retailers
Scan Results
Daily timeframeScienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. With a market capitalization of $4.7M, it sits in micro-cap territory. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen.
Market Cap
$4.7M
Beta
4.08
P/E (TTM)
—
P/E (Fwd)
-10.67
EPS (TTM)
$-54.27
EPS (Fwd)
$-0.27
ROE
-53.5%
ROA
-8.9%
Cash
$8.2M
Total Debt
$10.7M
Free CF
-$7.6M
52W Change
-92.7%
Annual Financials
Cash vs Debt
Where SCNX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, SCNX finished 67.56% below its 150-day moving average ($9.00) and 69.74% below its 200-day moving average ($9.65). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SCNX overbought or oversold?
At the October 20, 2026 close, SCNX's RSI(14) was 13.7, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, SCNX has $8.2M in cash with $10.7M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$7.6M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -53.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has pulled back from $10.3M (2022) to $432K (2025), a 96% decline worth watching.
A beta of 4.08 means SCNX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing SCNX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.